Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes are clonal bone marrow disorders characterized by ineffective hematopoiesis and recurrent genomic alterations relevant to targeted therapy.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Myelodysplastic Syndromes (MDS) in FDA labeling.
Defined at the solid tumor level and applicable to Myelodysplastic Syndromes (MDS) and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Myelodysplastic Syndromes (MDS). Select a therapy to view the specific approval and eligible tests.
PDGFRB (PDGFRB gene rearrangement at 5q31~33)
IDH1 (R132 mutations (R132C, R132H, R132G, R132S, and R132L))